Abstract. Thyroid cancer is the most common endocrine malignancy, with an increasing prevalence worldwide. Poorly-differentiated thyroid cancer (PDTC) is relatively rare and its prognosis is poor. To date, no ideal treatment strategy is available for patients with advanced recurrent PDTC, particularly for patients in crisis. However, partial success in treating thyroid cancer has been achieved with targeted therapy, and advances made in understanding the molecular biology of the tumor. The current study describes the case of a patient diagnosed with PDTC following presentation with hoarseness, orthopnea, and a large right neck mass. A transient partial response to sunitinib malate treatment was achieved for >3 months. In addition, the current study reviewed the relevant literature and discussed the therapeutic value of sunitinib as a more favorable treatment strategy for patients with advanced recurrent PDTC compared with the currently available treatments. Successful treatment with sunitinib, as well as molecular analysis of the tumor, occurred in the present case. Sunitinib was determined to have potential in treating thyroid tumors, however, larger prospective studies are required to validate the findings of the current case study prior to the application of this agent in clinical practice.

Introduction

Thyroid cancer is the most common endocrine malignancy (1), with an increasing incidence rate worldwide (2). Differentiated thyroid cancer (DTC) accounts for 80-90% of all cases of thyroid cancer and is primarily responsible for the increased incidence of this disease (3). By contrast, poorly-differentiated thyroid cancer (PDTC) represents only 5% of all cases of thyroid cancer cases (4); however, PDTC is more aggressive and is associated with worse outcomes compared with DTC. For patients with advanced DTC that is not suitable for radioiodine therapy, surgical resection or local therapy with external-beam radiation, there are only a limited number of therapeutic strategies available (5).

One-third of all patients with PDTC develop recurrent disease, and only 30% of patients with distant metastases may achieve complete remission with radioiodine therapy (6,7). As recurrent PDTC is aggressive and often associated with poor outcomes, these patients would primarily benefit from the development of novel therapeutic strategies (8). Recent studies have revealed information regarding the biological and molecular mechanisms underlying thyroid cancer, facilitating the identification of novel molecular targets for the treatment of the patients with PDTC. At present, the use of sunitinib for the treatment of thyroid cancers is under investigation [ClinicalTrials.gov identifiers, NCT00510640, NCT00381641 and NCT00668811], however, there are very few reports evaluating sunitinib for PDTC.

The present study describes a case of recurrent PDTC that was not amenable to any currently available therapeutic strategies, but was successfully treated with sunitinib. Written informed consent for this case report was obtained from the patient's family.

Case report

A 49-year-old female was referred to Tianjin Huanhu Hospital (Tianjin, China) in October 2013 due to the post-operative recurrence of PDTC and lung metastases.

The patient was initially admitted to the Affiliated Hospital of Inner Mongolia Medical College (Hohhot, Mongolia) in September 2012 with neck masses. The patient underwent resection of the right lobe of the thyroid and isthmus, as well as subtotal resection of the left lobe. A pathological examination revealed that the 40x30x40-mm tumor in the right lobe was a poorly-differentiated papillary thyroid carcinoma with partial neuroendocrine large-cell undifferentiated carcinoma and Hashimoto's thyroiditis, a type of PDTC. The tumor was immunoreactive to thyroid transcription factor 1, thyroglobulin and cytokeratin 19, with a Ki-67 labeling index of <70%. Otherwise, the left thyroid lobe and isthmus lesions were benign. The patient opted for treatment with herbal and
conservative traditional Chinese medicine alone (drug name and dose unknown), which was administered by a family doctor, as opposed to radiotherapy and/or chemotherapy due to the patient's concerns regarding possible side-effects. Two and a half months after surgery, fluorine-18 fluoro-deoxyglucose positron emission tomography/computed tomography (CT) revealed tumor recurrence in the resection site and metastases in the posterior basal segment of the lower lobe of the right lung. However, the patient insisted on the continuation of traditional Chinese medicine. The right neck mass became ulcerous in August 2013, with dyspnea appearing one month later and gradually worsening. The patient was eventually admitted to Tianjin Huanhu Hospital for further diagnosis and treatment. Despite weight loss of 10 kg over two months, the patient's disposition, diet and overall physical condition were adequate. In additional to traditional Chinese medicine, the patient had been taking thyroid tablets (dose, 120 mg daily) for hypothyroidism since undergoing surgery. Furthermore, the patient's diabetes had been managed with routine medication for three years, and no other medical problems or family history of malignancy were noted.

The patient's voice sounded hoarse with orthopnea upon physical examination. A large right neck mass was clearly visible, measuring 10x10 cm, and an area of skin ulceration of ~5x5 cm was present on the surface in the middle of the mass. A decrease in respiratory sounds was found for each lung and edema was notable in the right upper limb.

A CT scan revealed a large mass with uneven density in the right lobe of the thyroid. The trachea was compressed to the left in the neck, with CT indicating a right supraclavicular conglomerate of lymph nodes and multiple enlarged lymph nodes compressed in the tracheoesophageal groove and the right paratracheal space. Additionally, multiple metastases were present in the lungs (Fig. 1).
patient was selected to undergo treatment with sunitinib. Following approval by the Institutional Review Board of Tianjin Huanhu Hospital and receipt of written informed consent from the patient, sunitinib malate (Sutent®; Pfizer, Inc., New York, NY, USA) treatment commenced in October 2013 at a dose of 37.5 mg/day.

After only seven days of treatment, the dyspnea symptoms improved and the patient was able to sleep in a semi-supine position. The dyspnea completely disappeared one month later. A lasting response was observed over three months of therapy, with sunitinib successfully inducing the shrinkage of the large right neck mass and lung metastases (Figs. 1 and 2). CT indicated evidence of an objective response, according to the response evaluation criteria in solid tumors (RECIST) (9), indicating that the current patient exhibited a partial response to treatment with sunitinib (Fig. 1). During treatment, the patient experienced mild fatigue and the development of hand/foot syndrome was unavoidable. Grade III leukopenia was observed one month after therapy commenced, resulting in the temporary discontinuation of treatment for four weeks. At the end of January 2014, grade III thrombocytopenia was observed, thus, sunitinib treatment was terminated. The tumor eventually progressed and the patient succumbed to the disease in February 2014. The time to progression was 3.25 months.

Discussion

Primary thyroid cancer presents as one of four histological subtypes: Papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC), with PTC and FTC typically grouped together as DTC. DTC is conventionally treated using a combined approach of total thyroidectomy and radioactive iodine (RAI) therapy prior to thyroid-stimulating hormone suppression. Such an approach generally results in a good prognosis for patients with DTC, with a five-year disease-associated survival rate of 97.8% (2).

Despite the good initial outcome of surgery for the vast majority of patients, 10-15% experience recurrent disease, with ~5% exhibiting distant metastases at presentation (10). The clinical management of patients with recurrent and advanced disease is often challenging. Their response to conventional chemotherapy is typically poor, with commonly used cytostatic chemotherapeutic agents resulting in limited and transient response rates of 0-22%, and typically causing significant toxicity (11). In certain cases, repeated surgery may control locoregional disease, however, it is not a viable option in cases of anaplastic cancer, for which possible treatment strategies are limited due to almost universally poor outcomes (12). The tumor pathology of the current patient was complex, consisting of poorly-differentiated papillary thyroid carcinoma combined with partial neuroendocrine large-cell undifferentiated carcinoma. Due to the possibly difficult complete resection of the tumor and the patient's orthopnea, a second surgical procedure, RAI, external-beam radiation or chemotherapy were not ideal treatment strategies.

The management of patients with PDTC is challenging and controversial, with no effective treatment strategies available prior to the recent development of multi-targeted tyrosine kinase inhibitors (13). Recent advances in the understanding of the biology of thyroid cancer, including DTC, MTC and ATC, have enabled the identification of various important molecular changes in thyroid cancer cells. These changes provide the basis for developing targeted therapies that have been considered for the treatment of thyroid cancer (12).

Various diagnostic and prognostic molecular markers, including BRAF and RAS point mutations, RET/PTC and PAX8/PPARY gene rearrangements, mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), tumor protein p53, Wnt-β catenin, hypoxia-inducible factor 1α and nuclear factor-κB signaling pathways, microRNA profiles, and aberrant methylation, have been identified in >70% of DTC cases (14). Ras/Raf/MEK/ERK (MAPK) and PI3K/Akt/mammalian target of rapamycin are the two major signaling pathways indicated to be involved in thyroid cancer, and are closely associated with the promotion of cell survival, cell cycle progression, migration, proliferation, metabolism, tumorigenesis and angiogenesis (15). Furthermore, the most frequently observed nucleotide substitutions in DTC involve BRAF, RAS (H-, N- and K-RAS) and RET (16,17).

BRAF, an important regulator of thyroid protein expression and cell proliferation, and the most potent activator of the MAPK pathway, is commonly mutated in thyroid cancer. Previously, the presence of BRAF V600E has been associated with a higher prevalence of persistent and recurrent disease (18). As BRAF has been indicated to be involved in PTC and ATC, it is the focus of various studies regarding the development of targeted therapies for thyroid cancer (12). In addition, BRAF is associated with the overexpression of vascular endothelial growth factor (VEGF), a protein with a role in angiogenesis. VEGF and VEGF receptor (VEGFR), as well as various growth factors, including platelet-derived growth factor (PDGF) and fibroblast growth factor, are
often overexpressed in thyroid cancer cells, constituting a second group of possible targets for the treatment of thyroid cancer (12).

The Ras family of small GTPases is composed of K-, H- and N-Ras. These G-proteins are fundamental in the transduction of intracellular signals from the cell membrane, however, constitutive activation of these three genes has been observed in all thyroid tumors originating from follicular cells (FTC). Furthermore, RAS substitutions are frequently detected in ATC and PDTCs. The most commonly reported RAS mutations in thyroid tumors are those in codon 61 of N-RAS and in H-RAS, however, others have been described (19,20).

**RET** is a proto-oncogene that encodes a transmembrane tyrosine-kinase receptor. The gene is located on chromosome 10q11.2 and its activation stimulates various signaling pathways, including the MAPK cascade. **RET** is not typically expressed in the follicular cells of the thyroid gland, however, germline point mutations of RET have been identified in ~98% of all hereditary MTC cases and somatic RET mutations are present in ~40% (range, 30-70%) of sporadic cases (21).

In the current case, RAS, BRAF and RET mutation status was unavailable, as the patient did not wish to undergo tumor biopsies. We propose that these genes should be routinely surveyed in future cases for individualized therapy.

Sunitinib is an oral tyrosine kinase inhibitor that targets VEGFR-1, -2 and -3, RET, KIT, PDGF receptors α and β, FMS-like tyrosine kinase 3 and colony-stimulating factor receptor type 1 (22). In an initial open-label, phase II study (23), 43 patients with metastatic, iodine-refractory thyroid carcinoma of all histological subtypes (37 DTCs and 6 MTCs) exhibited biochemical and objective RECIST responses to six-week cycles (four weeks on and two weeks off) of sunitinib at a single daily dose of 50 mg. Of the 31 patients with DTC who completed two cycles of sunitinib therapy, 13% exhibited a partial response, 68% experienced stable disease, 10% experienced progressive disease and 9% were not evaluable. Thus, the objective response rate was 13% and the disease control rate was 81% (23). A second phase II trial (24) of sunitinib (37.5 mg daily) in patients with progressive DTC (n=28) or MTC (n=7) reported a complete response in 3% of patients, a partial response in 28% of patients and stable disease in 46% of patients. Toxicities included fatigue, neutropenia, hand-foot syndrome, diarrhea and leukopenia. In addition, one patient who was administered with anticogulation medication succumed due to gastrointestinal bleeding (24). A third open-label, phase II trial (ClinicalTrials.gov identifier, NCT00510640) has been completed, however, the study results have yet to be published. Furthermore, no phase III trial of sunitinib for the treatment of thyroid cancer has been conducted thus far.

In the present case, treatment with sunitinib resulted in a significant reduction in tumor size and caused symptom amelioration. A noticeable response was observed in the neck tumor, potentially providing opportunities for additional treatments. Therefore, the current study indicates that sunitinib may be a good treatment strategy for similar cases of PDTC. However, genetic testing should be considered for more individualized therapy and attention should be focused on possible adverse reactions, particularly hematological toxicity.

**Acknowledgements**

The authors would like to thank Dr Li Xiao Long, Department of Head and Neck Tumors at Tianjin Medical University Cancer Institute and Hospital (Tianjin, China), for providing technical assistance. The authors would also like to thank Dr Fu Le Jun from the Imaging Department at Tianjin Huanjin Hospital (Tianjin, China) for preparing the tumor images.

**References**
